Latest UCB Stories

Data Showed Reduced Nocturnal Systolic Blood Pressure Elevations and Periodic Limb Movements During Sleep in Restless Legs Syndrome (RLS) Patients ATLANTA, May 17, 2013 /PRNewswire/ -- UCB today announced data from a double-blind, placebo-controlled study that found that Neupro(®) (Rotigotine Transdermal System) reduced total nocturnal systolic blood pressure (NSBP) elevations associated with periodic limb movements during sleep (PLMS) and total PLMS in patients with idiopathic...

- Project Will Use Big Data and Analytics to Address Pressing Public Health Issue ARMONK, N.Y. and BRUSSELS, May 16, 2013 /PRNewswire/ -- regulated information -- UCB and IBM (NYSE:IBM) today announced the completion of the initial phase of a project designed to harness the power of analytics to help healthcare providers deliver more highly personalized care to people living with epilepsy. The milestone marks the critical first step in the path towards eventually harnessing the...

- Researchers will study factors influencing optimal epilepsy outcomes ATLANTA, March 25, 2013 /PRNewswire/ -- A research collaboration to analyze the clinical factors that impact epilepsy care and outcomes was announced today by the Department of Neurology at Emory University School of Medicine and UCB, a leading biopharmaceutical company. This work is part of an innovative research collaboration that seeks to identify factors and approaches that achieve optimal response in epilepsy...

Data from a non-interventional, observational study of 76 patients presented at the 65th American Academy of Neurology Annual Meeting ATLANTA, March 19, 2013 /PRNewswire/ -- UCB today announced data from a non-interventional, observational study conducted in Germany that found that when Parkinson's disease (PD) patients were switched from an oral PD medication to Neupro(®) (Rotigotine Transdermal System), they reported improvements in pre-existing gastrointestinal (GI) symptoms....

-- Top-line results demonstrate that the conversion to lacosamide monotherapy study met its primary endpoint ATLANTA and BRUSSELS, March 5, 2013 /PRNewswire/ -- regulated information - UCB today announced positive results of a Phase 3 study designed to evaluate the efficacy and safety of conversion to lacosamide monotherapy in adult patients with partial-onset seizures with or without secondary generalization compared with a historical control. The study met its primary endpoint...

Innovative collaboration launched with ConfometRx, the GPCR structural biology company founded by Stanford University professor and Nobel Prize winner Brian Kobilka PALO ALTO, Calif., Feb. 21, 2013 /PRNewswire-USNewswire/ -- ConfometRx announced today that it has sealed a research agreement with UCB to enable the discovery of novel medicines addressing unmet medical need in Neuroscience. Under this two-year multi-target agreement UCB and ConfometRx will leverage structural biology to...

LONDON, January 29, 2013 /PRNewswire/ -- ~ Tweet your questions ahead of The Pharma Summit 2013 at @EG_Healthcare ~ Should Pharma cut its losses and get out of R&D, or does it still have a role to play in medical research? The Economist Events is holding its 19th Annual Pharma Summit 2013 [http://www.economistconferences.co.uk/event/pharma-summit-2012/5796 ] in London on Thursday, 28th February 2013. The summit will...

ATLANTA, Dec. 5, 2012 /PRNewswire/ -- Health expert and patient advocate Dr. Donnica Moore and global biopharmaceutical company UCB, Inc. are launching Choose Your Move: Take Control of RLS to shed light on the real impact of Restless Legs Syndrome (RLS) and empower those living with the disease to work with their doctor to find a treatment approach that's right for them. "Unfortunately, many people do not fully understand what it's like to live with the disease," says Dr. Moore....

ATLANTA, Nov. 29, 2012 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring key sets of VIMPAT(® )(lacosamide) C-V data at the 66(th) Annual Meeting of the American Epilepsy Society (AES) in San Diego, Calif., November 30 - December 4. "UCB recognizes the importance of investing in clinical research and is proud to present VIMPAT(® )data that support our goal of gaining additional insight into the treatment of...

The Michael J. Fox Foundation teams with UCB, Inc. to share patient stories of living with Parkinson's disease NEW YORK, Nov. 19, 2012 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) has teamed up with the biopharmaceutical company UCB, Inc. to create the "Tell Us Your Story" Facebook campaign. The campaign aims to encourage members of the Parkinson's community to share their personal experience with the disease while raising dollars for...